Generating a Generation of Proteasome Inhibitors: From Microbial Fermentation to Total Synthesis of Salinosporamide A (Marizomib) and Other Salinosporamides

The salinosporamides are potent proteasome inhibitors among which the parent marine-derived natural product salinosporamide A (marizomib; NPI-0052; 1) is currently in clinical trials for the treatment of various cancers. Methods to generate this class of compounds include fermentation and natural pr...

Full description

Bibliographic Details
Main Authors: Barbara C. Potts, Kin S. Lam
Format: Article
Language:English
Published: MDPI AG 2010-03-01
Series:Marine Drugs
Subjects:
Online Access:http://www.mdpi.com/1660-3397/8/4/835/
id doaj-41e6ca02c2574891baf187d144d8ce11
record_format Article
spelling doaj-41e6ca02c2574891baf187d144d8ce112020-11-24T22:46:50ZengMDPI AGMarine Drugs1660-33972010-03-018483588010.3390/md8040835Generating a Generation of Proteasome Inhibitors: From Microbial Fermentation to Total Synthesis of Salinosporamide A (Marizomib) and Other SalinosporamidesBarbara C. PottsKin S. LamThe salinosporamides are potent proteasome inhibitors among which the parent marine-derived natural product salinosporamide A (marizomib; NPI-0052; 1) is currently in clinical trials for the treatment of various cancers. Methods to generate this class of compounds include fermentation and natural products chemistry, precursor-directed biosynthesis, mutasynthesis, semi-synthesis, and total synthesis. The end products range from biochemical tools for probing mechanism of action to clinical trials materials; in turn, the considerable efforts to produce the target molecules have expanded the technologies used to generate them. Here, the full complement of methods is reviewed, reflecting remarkable contributions from scientists of various disciplines over a period of 7 years since the first publication of the structure of 1. http://www.mdpi.com/1660-3397/8/4/835/salinosporamide AmarizomibNPI-0052proteasome inhibitortotal synthesissemi-synthesisnatural products chemistryfermentationmutasynthesisprecursor-directed biosynthesisstructure-activity relationshipsanalogs
collection DOAJ
language English
format Article
sources DOAJ
author Barbara C. Potts
Kin S. Lam
spellingShingle Barbara C. Potts
Kin S. Lam
Generating a Generation of Proteasome Inhibitors: From Microbial Fermentation to Total Synthesis of Salinosporamide A (Marizomib) and Other Salinosporamides
Marine Drugs
salinosporamide A
marizomib
NPI-0052
proteasome inhibitor
total synthesis
semi-synthesis
natural products chemistry
fermentation
mutasynthesis
precursor-directed biosynthesis
structure-activity relationships
analogs
author_facet Barbara C. Potts
Kin S. Lam
author_sort Barbara C. Potts
title Generating a Generation of Proteasome Inhibitors: From Microbial Fermentation to Total Synthesis of Salinosporamide A (Marizomib) and Other Salinosporamides
title_short Generating a Generation of Proteasome Inhibitors: From Microbial Fermentation to Total Synthesis of Salinosporamide A (Marizomib) and Other Salinosporamides
title_full Generating a Generation of Proteasome Inhibitors: From Microbial Fermentation to Total Synthesis of Salinosporamide A (Marizomib) and Other Salinosporamides
title_fullStr Generating a Generation of Proteasome Inhibitors: From Microbial Fermentation to Total Synthesis of Salinosporamide A (Marizomib) and Other Salinosporamides
title_full_unstemmed Generating a Generation of Proteasome Inhibitors: From Microbial Fermentation to Total Synthesis of Salinosporamide A (Marizomib) and Other Salinosporamides
title_sort generating a generation of proteasome inhibitors: from microbial fermentation to total synthesis of salinosporamide a (marizomib) and other salinosporamides
publisher MDPI AG
series Marine Drugs
issn 1660-3397
publishDate 2010-03-01
description The salinosporamides are potent proteasome inhibitors among which the parent marine-derived natural product salinosporamide A (marizomib; NPI-0052; 1) is currently in clinical trials for the treatment of various cancers. Methods to generate this class of compounds include fermentation and natural products chemistry, precursor-directed biosynthesis, mutasynthesis, semi-synthesis, and total synthesis. The end products range from biochemical tools for probing mechanism of action to clinical trials materials; in turn, the considerable efforts to produce the target molecules have expanded the technologies used to generate them. Here, the full complement of methods is reviewed, reflecting remarkable contributions from scientists of various disciplines over a period of 7 years since the first publication of the structure of 1.
topic salinosporamide A
marizomib
NPI-0052
proteasome inhibitor
total synthesis
semi-synthesis
natural products chemistry
fermentation
mutasynthesis
precursor-directed biosynthesis
structure-activity relationships
analogs
url http://www.mdpi.com/1660-3397/8/4/835/
work_keys_str_mv AT barbaracpotts generatingagenerationofproteasomeinhibitorsfrommicrobialfermentationtototalsynthesisofsalinosporamideamarizomibandothersalinosporamides
AT kinslam generatingagenerationofproteasomeinhibitorsfrommicrobialfermentationtototalsynthesisofsalinosporamideamarizomibandothersalinosporamides
_version_ 1725683540006273024